Press Release

Taysha Gene Therapies to Participate in Upcoming June Investor Conferences and Convention

06-02-2022   |  

Jefferies Healthcare Conference on June 8, 2022 at 9:30 am ET

Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 at 11:20 am PT

BIO International Convention on June 15, 2022 at 11:00 am PT

JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 pm ET

DALLAS, June 02, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a fireside chat at the Jefferies Healthcare Conference, Goldman Sachs 43rd Annual Global Healthcare Conference, and JMP Securities Life Sciences Conference. Additionally, RA Session II, CEO, President and Founder, will participate in a panel discussion at the BIO International Convention.

A webcast of the fireside chats will be available in the “Events & Media” section of the Taysha corporate website at Archived versions of the webcast will be available on the website for 90 days.

Conference Details: 
Event: Jefferies Healthcare Conference
Date: Wednesday, June 8
Time: 9:30 am ET
Format: Fireside chat
Event: Goldman Sachs 43rd Annual Healthcare Conference
Date: Tuesday, June 14
Time: 11:20 am PT
Format: Fireside chat
Event: BIO International Convention
Date: Wednesday, June 15
Time: 11:00 am PT
Format: Panel discussion
Topic: “A New Era in Gene Therapy”
Event: JMP Securities Life Sciences Conference
Date: Thursday, June 16
Time: 1:00 pm ET
Format: Fireside chat

About Taysha Gene Therapies        

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at

Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies

Media Contact:
Carolyn Hawley
Canale Communications 

Primary Logo

Source: Taysha Gene Therapies, Inc.